Dexmedetomidine HCl - Moligand™, 10mM in DMSO , Adrenergic receptor alpha-2 agonist, CAS No.145108-58-3, Adrenergic receptor alpha-2 agonist

CAS: 145108-58-3 Cat. No.: D409289 Summenformel: C₁₃H₁₆N₂·HCl Molekulargewicht: 236.74 EG-Nummer: 682-047-2

GRADE & PURITY Moligand™, 10mM in DMSO

Synonyms

5-​[(1S)​-​1-​(2,​3-​dimethylphenyl)​ethyl]​-​1H-​imidazole,hydrochloride (1:1)

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Übersicht

Information

Dexmedetomidine HCl is a highly selective and potent alpha-2 adrenoceptor agonist, which reduces anesthetic requirements for patients by providing significant sedation.
In vitro

In vivo

Cell Data

cell lines：

Concentrations：

Incubation Time：

Powder Purity:≥99%

Specifications

Synonyme

5-​[(1S)​-​1-​(2,​3-​dimethylphenyl)​ethyl]​-​1H-​imidazole,hydrochloride (1:1)

Spezifikationen & Reinheit

Moligand™, 10mM in DMSO

Biochemische und physiologische Mechanismen

Dexmedetomidine HCl is a highly selective and potent alpha-2 adrenoceptor agonist, which reduces anesthetic requirements for patients by providing significant sedation.

Storage

Store at -80°C

Verschickt in

Dry ice packs + Cold packs

Dieses Produkt erfordert Kühlkettenversand. Grundversand und andere Economy-Optionen sind nicht verfügbar.

Note

Moligand™

Aktionsart

AGONIST

Mechanismus der Wirkung

Adrenergic receptor alpha-2 agonist

Namen und Kennungen

• Isomere SMILES: CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C.Cl
• WGK Deutschland: 3
• RTECS: NI5156750
• Molekulargewicht: 236.74
• Reaxy-Rn: 5362300
• Reaxys-RN_link_address: https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=5362300&ln=

Chemische und physikalische Eigenschaften

• Löslichkeit: Solubility (25°C) In vitro Water: 34 mg/mL (198.65 mM); DMSO: 7 mg/mL (40.89 mM); Ethanol: Insoluble
• Spezifische Drehung [α]: 51° (C=1,H2O)
• Schmelzpunkt (°C): 158 °C

Referenzen

1. Kaiyu Xu, Ying Zhang, Yongxuan Chen, Xiaojia Zhu, Yu Li, Longbao Lv, Xiechao He, Zhengfei Hu, Yifan Li, Maosen Ye, Dewei Jiang, Zhanlong He, Weihua Jin, Yanyan Li, Xiaomei Yu, Deng-Feng Zhang, Karl Herrup, Ping Zheng, Yong-Gang Yao, Dong-Dong Wu, Jiali Li.  (2025)  ATM deficiency drives phenotypic diversity and Purkinje cell degeneration in a macaque model of ataxia-telangiectasia.  Cell Reports Medicine,      [PMID:40961921] [10.1016/j.xcrm.2025.102355]

2. Qiuxia Liao, Zhi Feng, Hairong Lin, Ye Zhou, Xinxin Lin, Xiao Lin, Huichang Zhuo.  (2025)  Dexmedetomidine improves septic acute kidney injury by inhibiting inflammation and oxidative stress through the activation of the Pink1/Park2 autophagy pathway.  RENAL FAILURE,      [PMID:40485166] [10.1080/0886022X.2025.2513677]

3. Ce Wu, Di Wu, LiJie Xie, HouYong Yan, Wei Zhang, Fei Yu.  (2026)  Near-Infrared Responsive Injectable Thermosensitive Hydrogel Sequentially Releases Dexmedetomidine and Ropivacaine for Postoperative Pain Management.  COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS,      [PMID:] [10.1016/j.colsurfa.2026.139503]